ClinConnect ClinConnect Logo
Search / Trial NCT06667414

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

Launched by HOFFMANN-LA ROCHE · Oct 30, 2024

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the genetic make-up of individuals who carry a specific mutation associated with Huntington Disease (HD). Researchers want to learn more about certain genetic variants, called single nucleotide polymorphisms (SNPs), that could be related to this condition. If you or a family member are between the ages of 25 and 60 and have been confirmed as a carrier of the HD gene mutation, you may be eligible to participate.

The study involves a single visit to a Huntington Disease clinic, where you will answer questions about your background and health history. At the end of the visit, a small blood sample will be taken for genetic testing. There are no specific health issues that would exclude you from participating, but you must be able to tolerate a blood draw. This study is currently looking for participants, and your involvement could help researchers better understand Huntington Disease and its genetic factors.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Have signed the Informed Consent Form (ICF)
  • Aged 25 to 60 years, inclusive, at the time of signing the ICF
  • Confirmation of Huntington Disease (HD) gene expansion mutation carrier status
  • Confirmation of Total Functional Capacity (TFC) ≥9 and Total Motor Score (TMS) \>6 within 12 months prior to signing the ICF
  • Ability to tolerate blood draws
  • Exclusion Criteria:
  • None

About Hoffmann La Roche

Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.

Locations

Chicago, Illinois, United States

Tampa, Florida, United States

Iowa City, Iowa, United States

Boston, Massachusetts, United States

Westmead, New South Wales, Australia

Parkville, Victoria, Australia

Madrid, , Spain

Phoenix, Arizona, United States

London, , United Kingdom

Ulm, , Germany

Edmonton, Alberta, Canada

Wellington, , New Zealand

Cambridge, , United Kingdom

Christchurch, , New Zealand

Ulm, , Germany

Montreal, Quebec, Canada

Toronto, Ontario, Canada

Ciudad Autonoma Buenos Aires, , Argentina

Sacramento, California, United States

Englewood, Colorado, United States

Baltimore, Maryland, United States

Pittsburgh, Pennsylvania, United States

Burgos, , Spain

Birmingham, Alabama, United States

Westmead, New South Wales, Australia

Erlangen, , Germany

La Jolla, California, United States

Halifax, Nova Scotia, Canada

Torres Vedras, , Portugal

Caulfield South, New South Wales, Australia

Kirkland, Washington, United States

Berlin, , Germany

Bochum, , Germany

Gda?Sk, , Poland

Warszawa, , Poland

Birmingham, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Clinical Trials

Study Director

Hoffmann-La Roche

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported